GeoVax Labs, Inc. (NASDAQ: GOVX, GOVXW), a biotechnology company developing human immunotherapies and vaccines against infectious diseases, closed its underwritten public offering of 2,560,000 units of its common stock, pre-funded warrants, and warrants for gross proceeds of $12.8 Million. The common stock and warrants began trading on The NASDAQ Capital Market on September 25, 2020, under the symbols “GOVX” and “GOVXW,” respectively. Lucosky Brookman represented the underwriter and book-running manager, Maxim Group LLC, in connection with the offering.
